Hello,

Welcome to our flagship newsletter, MarketBeat Daily Ratings.

We'll deliver the latest "Buy" and "Sell" ratings from Wall Street's top-rated analysts directly to your inbox each morning.

But first, we need you to do two quick things:

1. Hit reply, and send a simple "Yes." Just one word. This tells Google (and other emails providers) that you actually want to get our newsletter.

2. After that, this link to confirm your subscription. That will tell us that you received our welcome email and that we should start sending your daily report. 

Confirm your subscription here.

After you have completed these two steps, we would like to gift you a free copy of one of our most popular investing reports: 7 Stocks to Buy and Hold Forever. You can download the report with this link.

Thank you again for subscribing. We look forward to being an important part of your investing journey

Matthew Paulson
Founder and CEO, MarketBeat.

P.S. If you didn’t intend to subscribe, no problem—you can unsubscribe with this link.

(ARReply-161)

UnitedHealth Just Gave Wall Street a Clearer Turnaround Signal

Reported by Peter Frank. Publication Date: 7/30/2026.

UnitedHealth Group (NYSE: UNH) just delivered its clearest evidence yet that its turnaround is gaining traction.

That is good news for stockholders. The company remains one of the most important players in American healthcare, providing coverage for more than 48.5 million people through commercial insurance, Medicare and Medicaid. Its giant Optum unit supports more than 120 million consumers through a combination of healthcare delivery, pharmacy and technology operations.

Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (Ad)

A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor.

This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.

Click here to learn this company's name for free today

After a stunning setback last year, it may still take time to prove that the company has fully recovered. However, UnitedHealth has worked through higher medical costs, portfolio changes and significant pressure on profitability since then. Analysts have increasingly shifted in the company’s favor, and the share price has responded accordingly.

Given that healthcare is among the most resilient sectors of the economy, investors are well advised to pay attention.

UnitedHealth's Turnaround Gains Traction

After a severe contraction a year ago, the company’s latest headline numbers suggest that it has regained control.

UnitedHealth reported second-quarter revenue of $112 billion and earnings from operations of $8 billion, up from $5.2 billion a year earlier. The company’s UnitedHealthcare operations accounted for $86 billion in revenue and $3.9 billion in earnings. Its Optum unit generated $65.7 billion in revenue and $4 billion in earnings.

Overall, adjusted second-quarter earnings per share came in at $6.38, compared with $4.08 a year ago and well above the analyst consensus of $4.94.

In response, UnitedHealth raised its full-year 2026 adjusted earnings guidance to a range of $19.50 to $20 per share. The increase follows a previous guidance raise after the first quarter.

Strong Fundamentals Support the Recovery

The numbers behind the results were also convincing. Second-quarter net margin came in at 4.9%, while cash flow from operations reached $11.1 billion, or 1.9 times net income. The debt-to-capital ratio stood at 41.2% as of June 30, down from 43.9% at the end of 2025 and approaching management’s 40% target for the year.

Perhaps the most important figure in the report was the medical cost ratio, which improved to 86.7% from 89.4% a year earlier. The improvement was aided by tighter Medicare cost controls and improved Medicaid reimbursement, a clear signal that the company is regaining the pricing discipline it lost during a difficult stretch.

UnitedHealth also repurchased $4 billion of its common stock through mid-July 2026 and is on track to repurchase at least $5 billion for the full year.

Wall Street Sees Cautious Optimism

Analysts are optimistic, but not without some caution. The 27 analysts following the stock give the company a consensus rating of Moderate Buy. The average 12-month price target is $455.92, representing roughly 7% upside from current levels.

UnitedHealth’s regained footing has not gone unnoticed. Shares are up more than 50% over the past 12 months and nearly 30% this year.

The Stock Has Rebounded Sharply

This is a far cry from where UnitedHealth found itself last year, when the company suffered a historic plunge in April 2025. After revealing that Medicare Advantage medical utilization had spiked at roughly twice the rate management had anticipated, the company saw its shares suffer their worst single-day drop in more than 25 years, falling more than 20% from about $585 per share.

The company slashed its full-year 2025 adjusted earnings per share forecast to a range of $26 to $26.50, down sharply from its prior guidance of $29.50 to $30. Over the following weeks, UnitedHealth shares fell below $300.

Real Risks Still Warrant Caution

For more than a year, UnitedHealth has been working to reposition itself in response to changing market forces while improving its medical management and pricing.

Still, some skepticism is warranted. UnitedHealth’s own disclosures point to changes in healthcare law, cyber and data risks, shifts in Medicare and Medicaid reimbursement, government investigations, litigation, pricing mistakes, pressure on quality scores, and ongoing challenges in estimating and managing medical costs. Competitors, including CVS Health (NYSE: CVS), Elevance Health (NYSE: ELV), Cigna (NYSE: CI) and Humana (NYSE: HUM), also add pressure to the business.

These are not abstract concerns. They are ongoing issues faced by health insurers and providers across the medical sector, making them particularly relevant for a company with UnitedHealth’s size and reach across the broader healthcare ecosystem.

A Recovery in Progress

Still, the investment case is attractive. Second-quarter results showed stronger profitability, improved medical-cost performance and renewed management confidence, reflected in another guidance increase.

The company continues to generate enormous cash flow, has unmatched scale across key markets, and offers a combination of earnings growth and income. UnitedHealth’s annual dividend of $9.28 per share yields an attractive 2.16%.

For investors, UnitedHealth may look convincing, as long as they are willing to accept some operational and regulatory risk.

It is a highly scrutinized business, and that brings some unpredictability. However, it is also a company showing strong signs of restored balance and renewed operational momentum.